Identification of barriers to implementation of precision oncology in patients with rare cancers.

ABSTRACT: Established treatment options for rare cancers are limited by the small number of patients. The current comprehensive genomic profiling (CGP) testing might not fully exploit opportunities for precision oncology in patients with rare cancers. Therefore, we aimed to explore the factors associated with CGP testing utility in rare cancers and identify barriers to implementing precision oncology. Patients who underwent CGP testing at our institution between September 2019 and June 2021 were enrolled in this retrospective study. Based on their results, the patients received molecularly targeted drugs or immune checkpoint inhibitors. Univariate and multivariate analyses evaluated the association between patient characteristics and the proportion of patients receiving molecularly targeted drugs. O

SUBMITTER: Takamizawa S 

PROVIDER: S-EPMC11145155 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature